Navigation Links
Good news for some hard-to-treat hepatitis C patients
Date:6/16/2009

ST. LOUIS In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment. The findings, published in the June issue of Hepatology, offer a new option for hepatitis C patients, and may be effective even for those patients with factors that make their condition difficult to treat.

"This represents an important advance for difficult to treat hepatitis C patients who have failed to respond to traditional therapy," said Bruce Bacon, M.D., director of the division of gastroenterology and hepatology at Saint Louis University School of Medicine and co-director of the Saint Louis University Liver Center .

About 4 million people in the U.S. have been infected with hepatitis C; an estimated 10,000 to 12,000 people die from complications each year in this country. Hepatitis C is caused by a virus, transmitted by contact with blood, and may initially be asymptomatic. For patients who develop chronic hepatitis C infection, inflammation of the liver may develop, leading to fibrosis and cirrhosis (scarring of the liver), as well as other complications including liver cancer and death.

For patients with chronic hepatitis C, the prognosis varies. About half fully recover after an initial course of pegylated interferon and ribavirin anti-viral therapy that may last from six months to a year.

The remaining patients, known as non-responders, may improve but the virus is not eliminated. These patients are at greatest risk for worsening, and subsequent treatments have shown limited effectiveness for this group. In addition, those with genotype 1 (a particular genetic variation of the virus), those with high baseline virus levels, those with advanced liver disease and African American patients are all less likely to respond well to treatment.

The study looked at 515 patients at 44 different sites. Patients were given either one of two doses of daily consensus interferon and ribavirin, or no treatment.

For patients with less severe liver damage who had shown some response to initial treatment, the success rate was above 30 percent. The overall results showed that, for patients who had been unresponsive to initial treatment, consensus interferon and ribavirin worked for about 7 percent of patients given the lower dose and about 11 percent of patients given the higher dose of consensus interferon and ribavirin.

"This study shows that select patients who have failed to respond to prior therapy are candidates for retreatment with consensus interferon and ribavirin," Bacon said.


'/>"/>

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-398-5279
Saint Louis University
Source:Eurekalert

Related medicine news :

1. Hard-to-Treat Leukemia Cell Subtype Identified
2. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
3. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
4. Blood-clotting protein modified for people with hard-to-treat hemophilia
5. Relaxation training may improve control of hard-to-treat systolic hypertension
6. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
7. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
8. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
9. NEJM study points to new era in hepatitis C treatment
10. Resource for Those Living with Hepatitis C Announces Website Redesign
11. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... in Hackensack, N.J. has been honored by Enterprising Women magazine as one of ... the world’s top women business owners. Winners have demonstrated that they have fast-growth ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines device ... business. , Mirroring360 Pro enables educators, business professionals and individuals to stream or ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
Breaking Medicine Technology: